Related Experiment Video
Updated: Oct 18, 2025
09:01
Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
Published on: July 3, 2025
461
Robust inflammatory breast cancer gene signature using nonparametric random forest analysis
Alaa Zare1, Lynne-Marie Postovit2, John Maringa Githaka3
1Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Breast Cancer Research : BCR
|September 28, 2021
Summary
A new 59-gene signature accurately identifies inflammatory breast cancer (IBC), a rare and aggressive subtype. This discovery offers hope for identifying new therapeutic targets for this challenging disease.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer.
- Previous attempts to identify a robust IBC-specific molecular signature have been unsuccessful.
- IBC is found across all molecular subtypes of breast cancer.
Purpose of the Study:
- To identify a novel gene signature specific to inflammatory breast cancer.
- To achieve high accuracy in classifying IBC samples.
Main Methods:
- Development and validation of a 59-gene signature (G59).
- Testing the signature's accuracy on discovery, validation, and independent datasets.
- Analysis of gene enrichment pathways and cellular components.
Main Results:
- The G59 signature achieved 100% accuracy in discovery and validation sets (45/45).
- The signature demonstrated high accuracy (60/61) on an independent dataset.
- G59 is independent of estrogen receptor (ER)/HER2 status and molecular subtypes.
- Genes in G59 are enriched in plasma membrane proteins and interleukin/chemokine signaling pathways.
Conclusions:
- A novel, highly accurate IBC-specific gene signature (G59) has been identified.
- This signature is independent of established breast cancer classifications.
- The findings suggest potential targetable genomic drivers for IBC, opening new avenues for research.
